Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immunologic Endpoint In PREVENT-19 Trial

WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported data from the phase 3 PREVENT-19 trial and Study 307. PREVENT-19 data in both adults aged 18 and older and adolescents aged 12 through 17 showed

Related Keywords

Washington ,United States ,Gregory Glenn ,More Such Health News ,Novavax Inc ,Novavax ,Prototype ,Ov2373 ,Chieves ,Enspecified ,Immunologic ,Ndpoint ,Prevent ,Trial ,